China’s cervical cancer trends reveal plateau amid rising risk for older and rural women
en-GBde-DEes-ESfr-FR

China’s cervical cancer trends reveal plateau amid rising risk for older and rural women

14/10/2025 TranSpread

Cervical cancer is one of the most preventable malignancies, yet it remains the fourth leading cause of cancer death among women globally. China accounts for nearly one-fifth of the world’s female population, making the country's progress crucial to the global elimination effort. Despite large-scale screening programs and the introduction of HPV vaccination in 2016, coverage remains low—only about half of women aged 35–64 have been screened and less than 10% of girls have completed HPV vaccination. Persistent gaps in access, especially in rural and aging populations, limit progress toward the WHO’s “90-70-90” targets. Based on these challenges, it is essential to conduct in-depth studies on cervical cancer trends and control strategies.

A research team from the National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, analyzed cervical cancer data from 22 long-term cancer registries across China, together with international datasets from the International Agency for Research on Cancer. Their study (DOI: /10.20892/j.issn.2095-3941.2025.0386), published in Cancer Biology & Medicine on September 15, 2025, examined incidence and mortality trends from 2000 to 2020 and compared China’s progress with other Asia–Pacific countries. The findings reveal encouraging signs of stabilization nationally but highlight widening disparities by age and geography that threaten elimination targets.

Using Joinpointregression analysis, the study found that China’s age-standardized incidence rate (ASIR) rose from about 3 per 100,000 in 2000 to over 10 per 100,000 by 2016, with an average annual increase of 6.5%. Since 2016, both incidence and mortality have plateaued nationally. Urban women under 35 years showed declining incidence after 2009, likely due to improved awareness and early detection. However, rural women aged 35–64 years continued to experience increases, while those aged ≥65 years showed steadily rising incidence and mortality in both urban and rural areas.

When benchmarked against regional peers, China’s trends contrasted sharply with Australia and the Republic of Korea, which achieved consistent declines through nationwide HPV vaccination and high-quality screening. Japan exhibited rising incidence, and the Philippines showed increasing mortality despite stable incidence. The authors emphasize that China’s plateau marks a critical inflection point—but the continuing age and regional disparities call for urgent policy recalibration.

“China’s stabilization in cervical cancer rates is an encouraging signal, but we cannot overlook the inequities beneath it,” said Professor Wenqiang Wei, corresponding author of the study. “Older women and those in rural regions remain at disproportionate risk, largely due to limited access to vaccination, screening, and timely treatment. Achieving the WHO elimination goal will require not just technological advances but system-level equity—ensuring every woman, regardless of where she lives, receives the same standard of preventive care.”

The findings provide critical evidence for refining China’s national cervical cancer elimination roadmap. To accelerate progress, researchers recommend expanding school-based HPV vaccination, scaling up primary HPV testing with self-sampling options, and ensuring standardized treatment across healthcare levels. Integrating AI-assisted cytology and digital registries could further improve early detection. Strengthening coordination between public health programs and local governments will be vital to narrow the urban–rural gap. As China approaches the peak of its national burden around 2040, decisive and equitable interventions will determine whether the elimination of cervical cancer becomes a regional reality.

###

References

DOI

10.20892/j.issn.2095-3941.2025.0386

Original Source URL

https://doi.org/10.20892/j.issn.2095-3941.2025.0386

Funding Information

This work was supported by a grant from the National Key Research and Development Program of China (No. 2022YFC2409901) and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2021-I2M-1-011).

About Cancer Biology & Medicine

Cancer Biology & Medicine (CBM) is a peer-reviewed open-access journal sponsored by China Anti-cancer Association (CACA) and Tianjin Medical University Cancer Institute & Hospital. The journal monthly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The journal is indexed in SCOPUS, MEDLINE and SCI (IF 8.4, 5-year IF 6.7), with all full texts freely visible to clinicians and researchers all over the world (http://www.ncbi.nlm.nih.gov/pmc/journals/2000/).

Paper title: Cervical cancer burden and trends in China, 2000–2020: Asia-Pacific international comparisons and insights for elimination goals
Fichiers joints
  • Study flowchart.Cervical cancer burden and trends in China and selected Asia-Pacific countries, 2000–2020. This study flow summarizes the rationale, methods, main findings, and policy implications of the study. National data were derived from 22 long-standing cancer registries in China (2000–2020), complemented by GLOBOCAN Overtime data for Australia, the Republic of Korea, Japan, and the Philippines. Analyses estimated age-standardized incidence and mortality rates (ASIR, ASMR) by age group (<35, 35–64, 65–74, ≥75 y) and by urban–rural areas, using joinpoint regression to calculate annual percent change (APC) and average annual percent change (AAPC) with reference to key policy milestones (2009 national screening program, 2016–2017 HPV vaccine introduction). The results highlighted a plateau in incidence and mortality nationally and in urban areas after 2016, persistent increases among older women (≥65 years), and widening urban–rural disparities. International comparisons showed favorable declines in Australia and republic of Korea, in contrast to rising incidence in Japan and increasing mortality in the Philippines. Policy implications emphasize expanding HPV vaccination, scaling up HPV-based screening with self-sampling in underserved areas, and ensuring nationwide access to quality-assured treatment to achieve elimination goals.
14/10/2025 TranSpread
Regions: North America, United States, Asia, China, South Korea, Oceania, Australia
Keywords: Science, Life Sciences

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Témoignages

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Nous travaillons en étroite collaboration avec...


  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2025 by DNN Corp Terms Of Use Privacy Statement